Bill & Melinda Gates Foundation

Leinco Technologies is a company that specializes in the development of high-purity monoclonal antibodies, proteins, and various reagents specifically for the diagnostic and biopharmaceutical industries. They provide a range of services, including in vitro antibody and protein production, antibody conjugations, and cell banking. Leinco Technologies focuses on augmenting the early discovery process in life science research and diagnostics, as well as contributing to the innovative development of protein therapeutics. Their expertise in optimizing and adapting products enables clients to effectively meet their research and development needs.

Micron Biomedical is a clinical-stage biopharmaceutical company established in 2014 and located in Atlanta, Georgia. The company focuses on developing microneedle patches specifically for vaccines, including those for influenza and polio. Its innovative microneedle technology aims to improve protective and therapeutic effects while enhancing patient compliance and simplifying the administration process. By leveraging this technology, Micron Biomedical seeks to facilitate the development of effective vaccines, addressing important public health needs.

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Schrödinger develops a computational platform that facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform.

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.

Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

Antibody Solutions provides antigen design, polyclonal antibody generation, research and drug development for biopharmaceutical companies.

PhaSER Biomedical is Exploiting the 8HUM mouse, a unique mouse model with multiple utilities in drug discovery, and development.

Sail Biomedicines is a flagship pioneering company that is developing tomorrow's medicines today using life's language. Sail's platform combines first-in-class translatable circular RNA technology (Endless RNATM or eRNA) with unique programmable nanoparticles based on natural components to thoroughly program medications for the first time.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Micron Biomedical is a clinical-stage biopharmaceutical company established in 2014 and located in Atlanta, Georgia. The company focuses on developing microneedle patches specifically for vaccines, including those for influenza and polio. Its innovative microneedle technology aims to improve protective and therapeutic effects while enhancing patient compliance and simplifying the administration process. By leveraging this technology, Micron Biomedical seeks to facilitate the development of effective vaccines, addressing important public health needs.

Axmed is a business focuses on LMICs and strengthens the purchasing power of these markets to ensure the supply of cost-effective, high-quality medicines. We partner exclusively with authorized, high-quality pharmaceutical companies and certified caregivers to accelerate access to medicines.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

GE Healthcare is a multinational healthcare company based in Chicago, Illinois, that specializes in manufacturing a diverse range of medical equipment and technologies. Founded in 1892, the company offers products and services including medical imaging, information technologies, medical diagnostics, and patient monitoring systems. GE Healthcare also supports drug discovery and biopharmaceutical manufacturing through intelligent devices and data analytics. The company aims to enhance patient care and outcomes by providing innovative healthcare solutions utilized in hospitals, clinics, research institutions, and pharmaceutical companies globally. By focusing on precision health and digitizing healthcare, GE Healthcare seeks to improve productivity and health outcomes for patients and healthcare providers alike. Additionally, the company pursues an aggressive acquisition strategy to strengthen its presence in emerging markets and expand its life sciences portfolio.

Latham BioPharm Group (LBG) provides the insight, knowledge, and network to unite teams and technologies in the Life Sciences. They provide the depth of expertise necessary to advance your programs, by providing a range of life science services including business development, program management, CMC, quality, regulatory, and strategic consulting with proven experience in biodefense/pandemic response and strategic product development. Our team has an average of over 20 years’ experience and many have served as senior executives at companies ranging from start-ups to Fortune 200 companies. A number of us have also held senior level positions within the US government. For over twenty years, they have helped clients identify, evaluate, fund, manage, and monetize opportunities in a wide variety of business segments, generating over $1 billion in government funding and over $100 million in licensing fees and investments. On the front end, they assist clients in evaluating critical business decisions and connecting with the target markets to assess opportunities with our Strategy and Portfolio Analysis, Market Research, and Commercial and Government Asset Analysis offerings. They then assist in finding and securing funding through our Business Development and Non-Dilutive Funding Services. Once funded, they drive successful advancement to a targeted value-inflection point through our Program Management and Product Development Team services.

Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. This technology, developed over two decades, is designed to facilitate the rapid development and commercialization of vaccines and therapeutics aimed at preventing and treating infectious diseases. Aegis Life's innovative approach supports the pharmaceutical industry in accelerating the discovery, clinical development, and manufacturing processes for vaccines and treatments, particularly in response to emerging health threats such as COVID-19.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

DelSiTech, Ltd. is a technology specialist based in Turku, Finland, focused on developing and licensing long-term controlled drug delivery systems. Established in 2001, the company specializes in biodegradable silica-based implants and injectable formulations for the controlled release of small molecular drugs, biopharmaceuticals, and viral vectors. DelSiTech's innovative technology embeds active ingredients within a silica matrix, facilitating parenteral and local administration through injectable depot, implant, and eye drop dosage forms. By providing expertise in controlled release products, DelSiTech aims to address various drug-related challenges and support clients in the development of supergeneric solutions.

Zoetis Inc. is a leading company in the animal health sector, focused on the discovery, development, manufacturing, and commercialization of medicines, vaccines, and diagnostic products for both livestock and companion animals. The company's diverse product portfolio includes vaccines for various diseases, anti-infectives to combat infections, and parasiticides to eliminate parasites. Additionally, Zoetis offers pharmaceutical products for pain management, reproductive health, and dermatological conditions, as well as medicated feed additives for livestock. The company also provides diagnostic tools, including portable blood and urine analysis systems, rapid immunoassay tests, and other non-pharmaceutical products. With a significant revenue contribution from companion animals, particularly in the United States, Zoetis markets its offerings to veterinarians, livestock producers, and retail outlets globally. Founded in 1952 and headquartered in Parsippany, New Jersey, Zoetis has established itself as a key player in advancing animal health and well-being through a commitment to research and innovation.

Aspen Pharmacare Holdings Limited is a global pharmaceutical company headquartered in Durban, South Africa, specializing in the manufacture and supply of both branded and generic pharmaceutical products. It operates primarily through two segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a diverse range of products, including general anaesthetics, muscle relaxants, cytotoxic medications, and injectable anticoagulants, particularly focusing on low molecular weight heparins and Xa inhibitors. The company also engages in the contract production and supply of active pharmaceutical ingredients (APIs) and finished pharmaceuticals for third parties. With a presence in over 150 countries, Aspen serves various markets, including South Africa, Australia, and several nations across Europe and Asia. Its extensive capabilities in manufacturing encompass both API and finished dosage forms, addressing a wide array of therapeutic needs. Founded in 1850, Aspen has expanded its reach significantly through strategic acquisitions, enhancing its footprint in emerging markets and contributing to a diverse portfolio of healthcare solutions.

ExploRNA Therapeutics creates revolutionary advancements in the use of mRNA as a therapeutic platform, implements those ideas into distinct therapeutic programs, and provides technology, a therapeutic platform, and medicines to pharmaceutical partners.

Cyclica Inc. is a Toronto-based company that specializes in enhancing the drug discovery process through its integrated cloud-based platform, which leverages artificial intelligence and biophysics. The company offers two main technologies: Ligand Design, which generates novel molecules and filters them based on various properties, and Ligand Express, a platform that screens small-molecule drugs against structurally-characterized protein repositories to assess poly-pharmacological profiles. This innovative approach allows pharmaceutical scientists to identify potential ligand-protein interactions, prioritize lead candidates, and explore opportunities for drug repurposing while also understanding potential adverse effects. Cyclica has established a strategic partnership with AUM Biosciences and has been operational since its incorporation in 2010.

Contro is an online prescription and delivery service for sexual health and confidence products such as birth control and erectile dysfunction treatment. Contro, through its secure digital platform, allows individuals to take control of their personal wellness by offering a convenient, affordable and discreet subscription service. Offering a cancel anytime policy, Contro makes it easier than ever to obtain sexual health products in South Africa.

Bayer is a global enterprise based in Germany, specializing in life sciences with a strong focus on health care and agriculture. The company develops and commercializes a wide range of products, including pharmaceuticals, consumer health items, and crop science solutions. Bayer's pharmaceutical division offers a variety of medications, while its consumer health segment includes vitamins and food supplements. In agriculture, Bayer provides seeds and crop protection products, including pesticides, herbicides, and fungicides, significantly expanded through the acquisition of Monsanto. Additionally, Bayer is a leader in animal health, contributing to the well-being of both human and animal populations. Overall, Bayer aims to create innovative solutions that address critical challenges in health and nutrition.

Nuvisan Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. We deliver services ranging from a single test to fully integrated drug development programs.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Celanese is a global technology and specialty materials company that engineers and manufactures a diverse range of products essential for everyday living. It is one of the world’s largest producers of acetic acid and its derivatives, which play a crucial role in various industries, including coatings and adhesives. Additionally, Celanese produces specialty polymers utilized in automotive, electronics, medical, building, and consumer markets. The company also manufactures cellulose derivatives, notably used in cigarette filters. With a strong commitment to research and development, Celanese focuses on innovation and provides opportunities for growth and advancement within a performance-driven culture. Its products are integral to the food, beverage, and pharmaceutical industries, reflecting the company's broad impact on daily life.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in San Jose, California, that specializes in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to address life-threatening infections. The company’s lead product candidate, AR-301, is currently undergoing Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis is advancing several other candidates, including AR-105, a fully human IgG1 mAb in Phase II trials targeting the gram-negative bacterium P. aeruginosa, and AR-101, which is also in Phase II trials for hospital-acquired pneumonia caused by the same pathogen. Other projects in development include AR-401, AR-201, and AR-501, which target various serious infections. Aridis employs proprietary technology platforms to identify and manufacture potent mAbs derived from patients who have successfully overcome infections, enabling the production of therapeutics that are optimized for efficacy without requiring genetic modification. Founded in 2003, Aridis Pharmaceuticals is committed to providing innovative solutions for critical infections.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Elarex is a Canadian healthcare technology company commercializing its proprietary PT120 formulation technology which has proven to stabilize biologicals (including live vaccines!) so that they are as effective when stored at 40C as if they had been stored at -80C.

Providence Therapeutics is a biotechnology company that develops a personalized mRNA cancer vaccine designed to treat advanced ovarian cancer. The company's vaccine identifies tumor mutations and elicits an immune response against the tumor cells, enabling users to treat themselves and live life to the fullest. It aims to provide safe and effective medicines for people suffering from diseases with unmet medical needs. Scott Leary, Eric Marcusson, and Bradley Sorenson established the company in Toronto, Ontario in 2015.

MyDawa is an innovative online pharmacy that facilitates the purchase of a wide range of high-quality medications and wellness products through a mobile platform. By connecting patients directly to drug stores, MyDawa provides a convenient solution for accessing essential health products without incurring service fees, transaction costs, or delivery charges. This approach aims to make medications more affordable and accessible while addressing the challenges present in the pharmaceutical supply chain.

Schrödinger develops a computational platform that facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform.

Inventprise is a biotechnology company based in Redmond, Washington, focused on developing vaccines to combat infectious diseases. Established in 2012, the company is known for its 25-valent pneumococcal conjugate vaccine (PCV), which is supported by significant funding from the Bill and Melinda Gates Foundation, exceeding $100 million. This vaccine is specifically designed for large-scale distribution in low- and middle-income countries. In addition to vaccine development, Inventprise offers comprehensive contract manufacturing and development services, including quality control assays, batch records, and training. The company also operates a fully equipped quality control laboratory that conducts testing for identity, potency, purity, and stability, thereby assisting clients in addressing health disparities and promoting public health.

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of serious medical disorders. Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication, and has the potential to enhance patient compliance to treatment, and limit diversion for illicit use and accidental exposure to the sublingual formulations. The New Drug Application (NDA) was submitted to the FDA in October, 2012 seeking approval for treatment of opioid dependence. In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties. Probuphine is the first product to utilize ProNeura™, a novel, proprietary, long-term drug delivery technology. The ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease, where maintaining stable, round-the-clock blood levels of a drug can benefit the patient and improve medical outcomes. Finally, Titan is also entitled to royalty revenue of 8-10% of net sales of Fanapt® (iloperidone), an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG (“Novartis”) under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension). Substantially all of this future royalty revenue has been sold to Deerfield Management (“Deerfield”), a healthcare investment fund, in exchange for cash and debt considerations which have been used to advance the development of Probuphine and for general corporate purposes.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Atomwise, Inc. is a biotechnology company based in San Francisco that specializes in using deep learning artificial intelligence for small molecule drug discovery. Founded in 2012, Atomwise developed the AtomNet platform, which enables virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical approach that leverages experimental affinity measurements and protein structures. The company focuses on addressing over 600 unique disease targets and has established partnerships with more than 250 organizations, including pharmaceutical and biotechnology firms. Atomwise's technology has been recognized for its ability to unlock previously undruggable targets, and the company has raised significant funding to support its mission of accelerating drug discovery and development.

Dynavax Technologies Corporation is a biopharmaceutical company based in Emeryville, California, focused on developing and commercializing innovative vaccines. The company's primary product, HEPLISAV-B, is an approved hepatitis B vaccine designed to prevent infection from all known subtypes of the virus in adults aged 18 and older. Dynavax is also advancing its proprietary CpG 1018 adjuvant to enhance vaccine efficacy and is engaged in various collaborations aimed at developing adjuvanted vaccines for COVID-19, pertussis, and universal influenza. In addition to its commercial efforts, Dynavax is involved in research partnerships with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations to create new vaccine candidates. The company was originally founded in 1996 as Double Helix Corporation and rebranded to its current name in September 1996.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Almac Group is a contract development and manufacturing organization that provides a comprehensive array of services to pharmaceutical and biotech companies worldwide. Established over 40 years ago and privately owned, the company offers research and development, biomarker discovery, active pharmaceutical ingredient (API) manufacturing, formulation development, clinical trial supply, and commercial-scale manufacturing, among other services. With its headquarters in Craigavon, Northern Ireland, Almac has expanded its operations to various locations, including the UK, Ireland, the US, and Asia. The company employs over 4,500 staff and is committed to continuous investment in its offerings, which encompass biomarker and companion diagnostics, clinical trial data management, and biocatalytic API manufacture. Additionally, Almac Discovery, a division of the group, focuses on innovative oncology research and the early-stage development of novel cancer treatments in partnership with pharmaceutical companies.

MedinCell is an injectable slow-release drug specialist company.

Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare. The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organizations.

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

AbCellera is an antibody discovery and development company focused on overcoming the limitations of traditional discovery methods. By utilizing its integrated platform, AbCellera's experts rapidly search a diverse array of antibodies to identify the most effective candidates for clinical development. This streamlined approach allows for faster movement to clinical trials, ultimately benefiting patients sooner. The company has a strong track record of collaborating with both emerging biotechnology firms and established pharmaceutical companies, providing optimized solutions tailored to their needs. AbCellera employs proprietary technology and advanced data science to enhance its antibody discovery process, positioning itself as a strategic partner in the biopharmaceutical industry.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Schrödinger develops a computational platform that facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform.

Recursion Pharmaceuticals is a clinical-stage biotechnology company based in Salt Lake City, Utah, focused on transforming drug discovery through the integration of technology, particularly artificial intelligence, automation, and bioinformatics. Founded in 2013, the company utilizes a sophisticated drug discovery platform that includes various software solutions and robotic automation to enhance chemical compound selection, streamline experimental workflows, and evaluate drug efficacy. Key components of this platform involve tools for designing chemical compounds, planning complex experiments, and analyzing data to understand drug interactions and biological responses. By creating one of the largest proprietary biological and chemical datasets, Recursion aims to uncover new biological insights and expedite the development of innovative treatments, ultimately improving patient outcomes.

Scripps Research is a prominent independent, not-for-profit organization dedicated to advancing biomedical research aimed at enhancing human health. Established from the Scripps Metabolic Clinic in 1924, it has grown into one of the largest institutions of its kind, employing around 3,000 individuals across its campuses in La Jolla, California, and Jupiter, Florida. The institute is recognized for its significant contributions to the biomedical sciences, including the development of new treatments for various diseases such as cancer, rheumatoid arthritis, and hemophilia. Scripps Research is home to renowned scientists, including three Nobel laureates, who engage in cutting-edge research. Additionally, its graduate program in biology and chemistry is highly regarded, consistently ranking among the top ten programs in the United States.

Novartis is a global healthcare company headquartered in Switzerland, dedicated to addressing the evolving needs of patients worldwide through the development and manufacturing of innovative pharmaceuticals. The company focuses on a wide range of therapeutic areas, including oncology, rare diseases, neuroscience, immunology, respiratory, and cardio-metabolic conditions. Novartis is also active in medical nutrition, providing specialized nutritional solutions for individuals with specific dietary needs. Additionally, its animal health division develops advanced medicines aimed at improving the health and welfare of pets, farm animals, and farmed fish. The Genomics Institute of the Novartis Research Foundation plays a crucial role in bridging basic science and preclinical drug discovery, employing nearly 600 scientists to enhance drug development processes. Through its diverse portfolio and commitment to research, Novartis aims to transform patient care and improve health outcomes globally.

Manus Bio Inc. specializes in recreating plant processes within microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company focuses on converting sugar sources into a variety of applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. By integrating metabolic engineering, protein engineering, and systems biology, Manus Bio develops microbes that efficiently manufacture complex and bioactive natural products. The company operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. Formerly known as Manus Biosynthesis, Inc., the company adopted its current name in June 2018.

Ventria Bioscience is a privately held biopharmaceutical company with a product pipeline enabled by ExpressTec. ExpressTec is a patented, plant-based recombinant protein manufacturing technology that delivers a ten-fold higher recombinant protein yield than other plant-based systems. Ventria Bioscience's platform technology delivers meaningful and sustainable economic advantages by enabling new product opportunities that were not previously available. It can be used to develop new biotherapeutics, novel vaccines, reagents for biomanufacturing, and industrial and biofuel enzymes.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

AbCellera is an antibody discovery and development company focused on overcoming the limitations of traditional discovery methods. By utilizing its integrated platform, AbCellera's experts rapidly search a diverse array of antibodies to identify the most effective candidates for clinical development. This streamlined approach allows for faster movement to clinical trials, ultimately benefiting patients sooner. The company has a strong track record of collaborating with both emerging biotechnology firms and established pharmaceutical companies, providing optimized solutions tailored to their needs. AbCellera employs proprietary technology and advanced data science to enhance its antibody discovery process, positioning itself as a strategic partner in the biopharmaceutical industry.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.

Univercells is a provider of biomanufacturing solutions focused on making biologics, including vaccines and therapeutics, more accessible and affordable. The company offers innovative technologies designed to reduce manufacturing costs significantly, achieving up to 90% savings on the cost of goods and over 75% in capital investment. Their approach utilizes single-use technologies and integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode. Univercells also provides a range of biomanufacturing services, including scale-X hydro, scale-X carbo, and NevoLine, along with integrated support such as equipment confirmation, facility design, and bioprocess excellence. This comprehensive offering aids cell and gene therapy manufacturers in scaling their operations from research and development to commercial production, ultimately addressing global health challenges.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader that focuses on researching, developing, manufacturing, and marketing innovative medicines. The company specializes in a range of therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases. With its commitment to improving patient outcomes, Takeda is dedicated to delivering advanced pharmaceuticals and therapeutics, as well as vaccines. Founded in 1781 and headquartered in Japan, Takeda operates worldwide, with significant research and development facilities in locations such as Cambridge, Massachusetts, and San Diego, California. The company also engages in strategic investments through its venture capital arm, which supports early-stage companies and technologies that align with its therapeutic focus, fostering collaborations that leverage its extensive R&D capabilities. Takeda's mission is to enhance the quality of life for patients globally through continuous innovation and excellence in healthcare.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

Novavax, Inc. is a late-stage biotechnology company focused on the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. Its lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, targeted at treating seasonal influenza in older adults. Both candidates utilize Novavax's proprietary Matrix-M adjuvant to enhance immune responses. In addition, the company is advancing an RSV F vaccine for older adults and children, and it is developing nanoparticle vaccines against the Ebola virus and a combination respiratory vaccine for influenza and RSV. Novavax is also working on a COVID-19 vaccine, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company for development and commercialization. Established in 1987 and headquartered in Gaithersburg, Maryland, Novavax utilizes its recombinant technology platform to create highly immunogenic nanoparticles to address urgent global health needs.

Schrödinger develops a computational platform that facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform.

CureVac is a clinical-stage biopharmaceutical company based in Germany, focused on developing vaccines and therapies utilizing messenger RNA (mRNA). Founded in 2000, the company’s innovative approach involves using mRNA as a data carrier to instruct the body to produce proteins that can combat various diseases. CureVac's pipeline includes novel mRNA-based cancer immunotherapies, prophylactic vaccines for infectious diseases, and molecular therapies aimed at enhancing the body’s production of therapeutic proteins. Its most advanced candidate, CV9104, is currently in Phase IIb clinical trials for prostate cancer treatment. Additionally, CureVac has collaborated with GSK to create second-generation vaccines for seasonal influenza and COVID-19, as well as an avian influenza vaccine, while exploring other mRNA vaccine applications in oncology and various therapeutic areas.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Liquidia Technologies is a clinical biopharmaceutical company dedicated to developing and commercializing therapeutics that address unmet patient needs, primarily through its proprietary PRINT technology. This particle engineering platform allows for the precise production of uniform drug particles, enhancing the safety and efficacy of various treatments. The company is currently advancing two key product candidates: LIQ861, aimed at treating pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across diverse therapeutic areas and drug types. One of its marketed products is YUTREPIA, an inhalation powder for treating pulmonary arterial hypertension.

BlueWillow Biologics, a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, specializes in the development of intranasal vaccines and anti-infective products utilizing its patented nanotechnology platform. The company's innovative NanoStat vaccine technology incorporates a unique oil-in-water nanoemulsion, allowing for the effective delivery and adjuvant of various antigens. BlueWillow focuses on vaccines for respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, and HIV, as well as providing NanoBio Protect, a nasal antiseptic solution. The company also has a licensing agreement with Merck for the use of its adjuvant in intranasal vaccines for respiratory syncytial virus (RSV) and seasonal influenza. Founded in 1999 as a spin-off from the University of Michigan, BlueWillow Biologics aims to enhance mucosal immunity through its advanced vaccine technology.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.